Group 1 - The core viewpoint of the article highlights that Zhengye Biology (ZYBT) experienced a stock price increase of 3.18%, reaching $5.675 per share, with a total market capitalization of $269 million as of July 30 [1] - Financial data indicates that Zhengye Biology's total revenue for the year ending December 31, 2024, is projected to be 186 million RMB, reflecting a year-on-year decrease of 11.95% [1] - The net profit attributable to the parent company is reported to be 11.31 million RMB, showing a significant year-on-year decline of 64.04% [1] Group 2 - Zhengye Biology Holdings Limited is registered in the Cayman Islands and primarily operates through its domestic subsidiary, Jilin Zhengye Biological Products Co., Ltd [1] - The subsidiary focuses on the research, development, manufacturing, and sales of veterinary vaccines, particularly for livestock in the People's Republic of China [1]
正业生物上涨3.18%，报5.675美元/股，总市值2.69亿美元